References
Key articles
Centers for Disease Control and Prevention (CDC). Influenza (Flu). April 2018.Full text
Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 influenza season. MMWR Recomm Rep 2018;67(No. RR-3):1–20.Full text Abstract
Reference articles
1. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7:257-265. Abstract
2. Glezen WP, Taber LH, Frank AL, et al. Influenza virus infections in infants. Pediatr Infect Dis J. 1997;16:1065-1068. Abstract
3. Neuzil KM, Wright PF, Mitchel EF Jr, et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856-864. Abstract
4. Martin CM, Kunin CM, Gottlieb LS, et al. Asian influenza A in Boston, 1957-1958. Arch Intern Med. 1959;103:515-531. Abstract
5. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine. 1999;17(suppl 1):S3-S10. Abstract
6. Fukuda K, Kieny MP. Different approaches to influenza vaccination. N Engl J Med. 2006;355:2586-2587.Full text Abstract
7. Nicholson K, Wood JM, Zambon M, et al. Influenza. Lancet. 2003;362:1733-1745. Abstract
8. Zimmer SM, Burke DS. Historical perspective - Emergence of influenza A (H1N1) viruses. N Engl J Med. 2009;361:279-285. Abstract
9. Australian Government Department of Health. Australian Influenza Surveillance Report. No. 12, 2017. October 2017Full text
10. Centers for Disease Control and Prevention (CDC). Reconstruction of the 1918 influenza pandemic virus. July 2014. http://www.cdc.gov/ (last accessed 9 March 2017).Full text
11. Stephenson I, Zambon M. The epidemiology of influenza. Occup Med (Lond). 2002;52:241-247. Abstract
12. Klimov A, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995;172:1352-1355. Abstract
13. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010;59:1057-1062.Full text Abstract
14. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS One. 2013;8:e66312.Full text Abstract
15. Centers for Disease Control and Prevention (CDC). Influenza (Flu). April 2018.Full text
16. Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017 May 15;35(21):2775-2780.Full text Abstract
17. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661-1665. Abstract
18. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366:1165-1174. Abstract
19. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2018-2019. Pediatrics. 2018 Oct;142(4).Full text Abstract
20. Hutchinson AF, Ghimire AK, Thompson MA, et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007;101:2472-2481. Abstract
21. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Jun 26;6:CD002733.Full text Abstract
22. Bekkat-Berkani R, Wilkinson T, Buchy P, et al. Seasonal influenza vaccination in patients with COPD: a systematic literature review. BMC Pulm Med. 2017 May 3;17(1):79.Full text Abstract
23. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-1332.Full text Abstract
24. Centers for Disease Control and Prevention (CDC). Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. December 2012. www.cdc.gov/ (last accessed 9 March 2017).Full text
25. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35:370-377. Abstract
26. Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther. 2007;29:2246-2255. Abstract
27. Mehta SR, Afenyi-Annan A, Byrns PJ, et al. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician. 2006;74:303-310. Abstract
28. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28:222-242. Abstract
29. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One. 2011;6:e29249.Full text Abstract
30. McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013;158:19-26.Full text Abstract
31. Madhi SA, Cutland CL, Kuwanda L, et al.; Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371:918-931.Full text Abstract
32. Kumar D, Campbell P, Hoschler K, et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation. 2016;100:662-669. Abstract
33. Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. December 2017 [internet publication].Full text
34. Centers for Disease Control and Prevention (CDC). Influenza vaccination in pregnancy: practices among obstetrician-gynecologists - United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep. 2005;54:1050-1052.Full text Abstract
35. Nunes MC, Aqil AR, Omer SB, Madhi SA. The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. Am J Perinatol. 2016 Sep;33(11):1104-14.Full text Abstract
36. American College of Obstetricians and Gynecologists. Influenza vaccination during pregnancy. ACOG Committee Opinion No. 732. Obstet Gynecol 2018;131:e109–14.Full text Abstract
37. Polyzos KA, Konstantelias AA, Pitsa CE, et al. Maternal influenza vaccination and risk for congenital malformations: a systematic review and meta-analysis. Obstet Gynecol. 2015;126:1075-1084. Abstract
38. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-45.Full text Abstract
39. Bernstein HH, Starke JR; American Academy of Pediatrics; et al. Policy statement - recommendation for mandatory influenza immunization of all health care personnel. Pediatrics. 2010;126:809-815. Abstract
40. Lorenc T, Marshall D, Wright K, et al. Seasonal influenza vaccination of healthcare workers: systematic review of qualitative evidence. BMC Health Serv Res. 2017 Nov 15;17(1):732.Full text Abstract
41. Ng AN, Lai CK. Effectiveness of seasonal influenza vaccination in healthcare workers: a systematic review. J Hosp Infect. 2011;79:279-286. Abstract
42. Centers for Disease Control and Prevention (CDC). Prevention strategies for seasonal influenza in healthcare settings. February 2018 [internet publication].Full text
43. Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010;10:71. Abstract
44. Beyer WE, Nauta JJ, Palache AM, et al. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine. 2011;29:5785-5792. Abstract
45. Demicheli V, Jefferson T, Ferroni E, et al Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018 Feb 1;2:CD001269.Full text Abstract
46. Bitterman R, Eliakim-Raz N, Vinograd I, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018 Feb 1;2:CD008983.Full text Abstract
47. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2018 Feb 1;2:CD004879.Full text Abstract
48. Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018 Feb 1;2:CD004876.Full text Abstract
49. Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017 Nov;75(5):381-394.Full text Abstract
50. Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin Infect Dis. 2017 Oct 15;65(8):1388-1395.Full text Abstract
51. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 influenza season. MMWR Recomm Rep 2018;67(No. RR-3):1–20.Full text Abstract
52. Englund JA, Walter E, Black S, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J. 2010;29:105-110. Abstract
53. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2018-2019. Pediatrics. 2018 Oct;142(4).Full text Abstract
54. Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 9;67(5):156-157.Full text Abstract
55. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Infant hospitalizations and mortality after maternal vaccination. Pediatrics. 2018 Feb 20. pii: e20173310.Full text Abstract
56. Thompson MG, Kwong JC, Regan AK, et al; PREVENT Workgroup. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. Clin Infect Dis. 2018 Oct 11. [Epub ahead of print].Full text Abstract
57. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. February 2018 [internet publication].Full text
58. Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130:25-43. Abstract
59. Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999;281:908-913.Full text Abstract
60. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-1663.Full text Abstract
61. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282:137-144.Full text Abstract
62. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994;169:68-76. Abstract
63. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355:2513-2522.Full text Abstract
64. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49-57.Full text Abstract
65. Manzoli L, Ioannidis JP, Flacco ME, et al. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother. 2012;8:851-862.Full text Abstract
66. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36-44. Abstract
67. Monto AS, Rotthoff J, Teich E, et al. Detection and control of outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004;39:459-464. Abstract
68. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-1381.Full text Abstract
69. De Villiers PJ, Steele AD, Hiemstra LA, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine. 2009;28:228-234. Abstract
70. Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ. 2004;329:660.Full text Abstract
71. Cools HJ, Gussekloo J, Remmerswaal JE, et al. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. J Med Virol. 2009;81:908-914. Abstract
72. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635-645.Full text Abstract
73. Nace DA, Lin CJ, Ross TM, et al. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis. 2015;211:1915-1924.Full text Abstract
74. Lehmann HC, Hartung HP, Kieseier BC, et al. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010;10:643-651. Abstract
75. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339:1797-1802. Abstract
76. Centers for Disease Control and Prevention (CDC). Influenza signs and symptoms and the role of laboratory diagnostics. October 2016 [internet publication].Full text
77. Call SA, Vollenweider MA, Hornung CA, et al. Does this patient have influenza? JAMA. 2005;293:987-997. Abstract
78. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest. 1998;101:643-649.Full text Abstract
79. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243-3247.Full text Abstract
80. Nicholson KG, Kent J, Hammersley V, et al. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997;315:1060-1064.Full text Abstract
81. Vesikari T, Beran J, Durviaux S, et al. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol. 2012;53:22-28. Abstract
82. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003;36:299-305. Abstract
83. Glezen WP. Influenza viruses. In: Feigin RD, Cherry JD, Demmler GJ, et al., eds. Textbook of pediatric infectious diseases. 5th ed. Philadelphia, PA: WB Saunders; 2004:2252-2269.
84. Govaert TM, Dinant GJ, Aretz K, et al. The predictive value of influenza symptomatology in elderly people. Fam Pract. 1998;15:16-22.Full text Abstract
85. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc. 2002;50:1498-1503. Abstract
86. Neuzil KM, O'Connor TZ, Gorse GJ, et al. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis. 2003;36:169-174.Full text Abstract
87. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis. 2006;43:564-568.Full text Abstract
88. Advisory Committee on Immunization Practices. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2013-2014. MMWR Recomm Rep. 2013;62:1-43. [Erratum in: MMWR Recomm Rep. 2013;62:906.]Full text Abstract
89. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018 Aug 31;67(6):e1-e94.Full text Abstract
90. Merckx J, Wali R, Schiller I, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. Ann Intern Med. 2017 Sep 19;167(6):394-409. Abstract
91. Bruning AHL, Leeflang MMG, Vos JMBW, et al. Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis. Clin Infect Dis. 2017 Sep 15;65(6):1026-1032.Full text Abstract
92. Petrozzino JJ, Smith C, Atkinson MJ. Rapid diagnostic testing for seasonal influenza: an evidence-based review and comparison with unaided clinical diagnosis. J Emerg Med. 2010;39:476-490. Abstract
93. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994;18:501-513. Abstract
94. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 Oct 20;282(15):1440-6.Full text Abstract
95. Wald TG, Miller BA, Shult P, et al. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc. 1995;43:170-174. Abstract
96. Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):71-76.Full text Abstract
97. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red book: 2006 report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:561.
98. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-1928. Abstract
99. Wendt CH, Hertz MI. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect. 1995;10:224-231. Abstract
100. Denny FW, Clyde WA Jr. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr. 1986;108:635-646. Abstract
101. Frank AL, Couch RB, Griffis CA, et al. Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol. 1979;10:32-36. Abstract
102. Ray CG, Minnich LL. Efficiency of immunofluorescence for rapid detection of common respiratory viruses. J Clin Microbiol. 1987;25:355-357. Abstract
103. Osiowy C. Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay. J Clin Microbiol. 1998;36:3149-3154. Abstract
104. World Health Organization. Who is more at risk of severe illness? What about other risks? February 2010. http://www.who.int (last accessed 9 March 2017).Full text
105. Fox JP, Cooney MK, Hall CE, et al. Influenza virus infection in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982;116:228-242. Abstract
106. Cox NJ, Fukuda K. Influenza. Infect Dis Clin North Am. 1998;12:27-38. Abstract
107. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. February 2018 [internet publication].Full text
108. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-24.Full text Abstract
109. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003-1032.Full text Abstract
110. Public Health England. Influenza: treatment and prophylaxis using anti-viral agents. October 2017.Full text
111. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106.Full text Abstract
112. Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ. 2009;339:b3172.Full text Abstract
113. Doll MK, Winters N, Boikos C, et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017 Nov 1;72(11):2990-3007. Abstract
114. Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis. Clin Infect Dis. 2017 May 15;64(10):1328-1334. Abstract
115. Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011;62:14-25. Abstract
116. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965.Full text Abstract
117. Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.Full text Abstract
118. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545.Full text Abstract
119. Cohen D. Complications: tracking down the data on oseltamivir. BMJ. 2009;339:b5387. [Erratum in: BMJ. 2010;340:c406.] Abstract
120. Doshi P. Neuraminidase inhibitors - the story behind the Cochrane review. BMJ. 2009;339:b5164. Abstract
121. Jefferson T, Doshi P, Thompson M, et al. Ensuring safe and effective drugs: who can do what it takes? BMJ. 2011;342:c7258. Abstract
122. Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med. 2009;361:e110. Abstract
123. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385:1729-1737. Abstract
124. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303-313. Abstract
125. Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;(1):CD002744.Full text Abstract
126. Stiver G. The treatment of influenza with antiviral drugs. CMAJ. 2003;168:49-56.Full text Abstract
127. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235.Full text Abstract
128. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51:887-894.Full text Abstract
129. National Institute for Health and Care Excellence. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. September 2008. http://www.nice.org.uk/guidance/TA158/ (last accessed 9 March 2017).Full text
130. Schwarzmann SW, Adler JL, Sullivan RJ Jr, et al. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971;127:1037-1041. Abstract
131. Azuma A, Kudoh S, Nakashima M, et al. Antipyretic and analgesic effects of zaltoprofen for the treatment of acute upper respiratory tract infection: verification of a noninferiority hypothesis using loxoprofen sodium. Pharmacology. 2011;87:204-213. Abstract
132. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007;(2):CD001269. Abstract
133. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175-1181. Abstract
134. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus Pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18(suppl 1):1-9. Abstract
135. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.Full text Abstract
136. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. PubMed PMID: 30184455. Abstract
137. McAllister L, Anderson J, Werth K, et al. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet. 2014;384:674-681. Abstract
138. Moscona A. Medical management of influenza infection. Annu Rev Med. 2008;59:397-413. Abstract
139. Ilyushina NA, Hoffmann E, Salomon R, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12:363-370. Abstract
140. Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2010;54:126-133.Full text Abstract
141. Ilyushina NA, Bovin NV, Webster RG, et al. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006;70:121-131. Abstract
142. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.Full text Abstract
143. Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010;202:234-241.Full text Abstract
144. Wu C, Chen W, Chen J, H. Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo. J Biochem. 2015;157:539-548. Abstract
145. Švančarová P, Svetlíková D, Betáková T. Induction of interferon lambda in influenza a virus infected cells treated with shRNAs against M1 transcript. Acta Virol. 2015;59:148-155. Abstract
146. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446-454.Full text Abstract
147. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008;78:91-102.Full text Abstract
148. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 2009;27:2506-2512. Abstract
149. Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 2010;28:2565-2572. Abstract
150. Influenza Vaccine 2007-2008. Med Lett Drugs Ther. 2007;49:81. Abstract
151. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007;150:306-310. Abstract
152. Winther B, Block SL, Reisinger K, et al. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. Int J Pediatr Otorhinolaryngol. 2010;74:684-688. Abstract
153. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828. Abstract
154. Gamboa ET, Eastwood AB, Hays AP, et al. Isolation of influenza virus from muscle in myoglobinuric polymyositis. Neurology. 1979;29:1323-1335. Abstract
155. Dell KM, Schulman SL. Rhabdomyolysis and acute renal failure in a child with influenza A infection. Pediatr Nephrol. 1997;11:363-365. Abstract
156. Dietzman DE, Schaller JG, Ray CG, et al. Acute myositis associated with influenza B infection. Pediatrics. 1976;57:255-258. Abstract
157. Brinar VV, Habek M, Brinar M, et al. The differential diagnosis of acute transverse myelitis. Clin Neurol Neurosurg. 2006;108:278-283. Abstract
158. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130-1136. Abstract
159. MacDonald K, Osterholm M, Hedberg C, et al. Toxic shock syndrome: a newly recognized complication of influenza and influenza-like illness. JAMA. 1987;257:1053-1058. Abstract
160. US Food & Drug Administration. FDA warns of fraudulent and unapproved flu products. March 2018 [internet publication].Full text
Use of this content is subject to our disclaimer